Literature DB >> 18486581

Diabetes and fragility fractures - a burgeoning epidemic?

Sol Epstein1, Derek LeRoith2.   

Abstract

Diabetes and osteoporosis are both diseases of epidemic proportions whose incidence is increasing worldwide. The etiology of osteoporosis is multifactorial and may differ for type 1(T1DM) as compared to type 2 (T2DM). Fragility fractures are common to both types of diabetes with hip fractures occurring more frequently in the elderly T2DM population. The use of oral PPAR gamma agonists in the treatment of T2DM has also added to the risk of fracture. This perspective discusses the etiologies and issues relating to the association of diabetes with osteoporosis and fractures and suggests some theories to clarify the underlying pathophysiology. Unfortunately at this time treatment for osteoporosis and fractures remains empirical.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18486581     DOI: 10.1016/j.bone.2008.03.017

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  14 in total

1.  The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.

Authors:  Emily Jane Gallagher; Hui Sun; Caroline Kornhauser; Aviva Tobin-Hess; Sol Epstein; Shoshana Yakar; Derek LeRoith
Journal:  Diabetes Metab Res Rev       Date:  2014-03       Impact factor: 4.876

2.  Bone microarchitecture, biomechanical properties, and advanced glycation end-products in the proximal femur of adults with type 2 diabetes.

Authors:  Lamya Karim; Julia Moulton; Miranda Van Vliet; Kelsey Velie; Ann Robbins; Fatemeh Malekipour; Ayesha Abdeen; Douglas Ayres; Mary L Bouxsein
Journal:  Bone       Date:  2018-05-30       Impact factor: 4.398

3.  The post-fracture care gap among Canadian First Nations peoples: a retrospective cohort study.

Authors:  W D Leslie; S L Brennan; H J Prior; L M Lix; C Metge; B Elias
Journal:  Osteoporos Int       Date:  2012-01-03       Impact factor: 4.507

4.  Urinary Pentosidine levels negatively associates with trabecular bone scores in patients with type 2 diabetes mellitus.

Authors:  Y J Choi; S Y Ock; Y Jin; J S Lee; S H Kim; Y -S Chung
Journal:  Osteoporos Int       Date:  2018-01-10       Impact factor: 4.507

5.  Sugar and bone: a not-so sweet story.

Authors:  Clifford J Rosen
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

Review 6.  Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review.

Authors:  Panagiotis Anagnostis; Stavroula A Paschou; Nifon N Gkekas; Aikaterini-Maria Artzouchaltzi; Konstantinos Christou; Dimitrios Stogiannou; Andromachi Vryonidou; Michael Potoupnis; Dimitrios G Goulis
Journal:  Endocrine       Date:  2018-02-06       Impact factor: 3.633

7.  Elevated incidence of fractures in solid-organ transplant recipients on glucocorticoid-sparing immunosuppressive regimens.

Authors:  B J Edwards; A Desai; J Tsai; H Du; G R Edwards; A D Bunta; A Hahr; M Abecassis; S Sprague
Journal:  J Osteoporos       Date:  2011-09-12

8.  Hyperglycemia increases the expression levels of sclerostin in a reactive oxygen species- and tumor necrosis factor-alpha-dependent manner.

Authors:  Jiho Kang; Kanitsak Boonanantanasarn; Kyunghwa Baek; Kyung Mi Woo; Hyun-Mo Ryoo; Jeong-Hwa Baek; Gwan-Shik Kim
Journal:  J Periodontal Implant Sci       Date:  2015-06-08       Impact factor: 2.614

9.  Relationship of Dickkopf1 (DKK1) with cardiovascular disease and bone metabolism in Caucasian type 2 diabetes mellitus.

Authors:  Antonia Garcia-Martín; Rebeca Reyes-Garcia; Beatriz García-Fontana; Sonia Morales-Santana; Ana Coto-Montes; Manuel Muñoz-Garach; Pedro Rozas-Moreno; Manuel Muñoz-Torres
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

10.  Comparison of fracture rates between indigenous and non-indigenous populations: a systematic review protocol.

Authors:  Sharon L Brennan-Olsen; Shae E Quirk; William D Leslie; Maree Toombs; Kara L Holloway; Sarah M Hosking; Julie A Pasco; Brianna J Doolan; Richard S Page; Lana J Williams
Journal:  BMJ Open       Date:  2016-08-26       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.